Author

J. Moreaux

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

G. Cartron· 2 shared A. Aze· 1 shared A. Constantinou· 1 shared A. Galy· 1 shared A. Ma· 1 shared A. Pruvost· 1 shared B. Kim· 1 shared C. Bellanger· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Cartron

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single-hit genome edition for expression of single-chain immunoglobulins by edited B cells

N. Ueda, M. Cahen, c. sirac, A. Galy, J. Moreaux, Y. Danger, M. Cogne

This paper develops a method to redirect B cells to express single-chain immunoglobulins by editing a single genomic locus, validated in cell lines and primary B cells.

bioRxiv · Jun 2, 2022 · PreprintImmunology

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

R. Paolillo, M. Boulanger, P. Gatel, L. Gabellier, D. Tempe, R. Hallal, M. De Toledo, J. Moreaux, H. Baik, E. Gueret, C. Recher, J.-E. Sarry, G. Cartron, M. Piechaczyk, G. Bossis

This study identifies NOX2 as a marker of poor prognosis and a contributor to chemoresistance in AML, showing its upregulation in drug-resistant cells and association with adverse outcomes.

bioRxiv · Mar 4, 2021Cancer Biology

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma

L. Herviou, F. IZARD, O. Karmous-Gadacha, C. Gourzones, C. Bellanger, E. Desmedt, A. Ma, L. Vincent, G. Cartron, J. Jin, E. De Bruyne, C. Grimaud, E. JULIEN, J. Moreaux

This study shows that inhibiting SETD8 reduces multiple myeloma cell survival and overcomes drug resistance regardless of p53 status.

bioRxiv · Sep 20, 2019Cancer Biology

Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites.

J. Basbous, A. Aze, L. Chaloin, R. Lebdy, D. Hodroj, C. Ribeyre, M. Larroque, C. Shepard, B. Kim, A. Pruvost, J. Moreaux, D. Maiorano, M. Mechali, A. Constantinou

This study shows dihydropyrimidines are cytotoxic metabolites that cause DNA replication stress and DPCs, suggesting DHP inhibition could target solid tumors.

bioRxiv · Mar 5, 2019Cancer Biology